Oragenics, Inc.
OGEN · AMEX
Bulios Fair Price
$0.55
13.1% upside
Current Price
$0.49
According to Bulios Fair Price, OGEN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Oragenics Inc. (OGEN) is a biotechnology company focused on the development and commercialization of therapeutic and diagnostic products in the field of medical microbiomics. With a product portfolio including drugs and diagnostic tests targeting the treatment of infectious diseases and improvement of microbiome health, Oragenics plays a key role in research and development of new therapeutic and diagnostic approaches. The company focuses on utilizing knowledge of the microbiome to discover new therapeutic targets and diagnostic markers, which may lead to the development of more effective drugs and diagnostic tools. With growing awareness of the importance of the microbiome for human health and the need for innovative therapeutic methods and diagnostic tests, Oragenics has the potential for further growth and development. OGEN shares could be suitable for investors seeking exposure in the biotechnology sector with a focus on microbiome and innovative therapeutic and diagnostic approaches.
Sector
Healthcare
Industry
Biotechnology
CEO
Janet Huffman
Employees
3
Headquarters
Lakewood Ranch
Upcoming events
Earnings
Upcoming earnings report